Diabetologia (1991) 34:416-422 
0012186X9100090J Diabetologia 
9 Springer-Verlag 1991 
Hyperinsulinaemia: the key feature of a cardiovascular 
and metabolic syndrome 
E. Ferrannini 2, 3, S. M. Haff~er l, B. D. Mitchell 1 and M. P. Stern 1 
Divisions of ' Clinical Epidemiology and 2Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, 
San Antonio, Texas, USA, and 3 Metabolism Unit of the C.N.R. Institute of Clinical Physiology, University of Pisa, Pisa, Italy 
Summary. In a population-based survey of 2,930 subjects, 
prevalence rates for obesity, Type 2 (non-insulin-dependent) 
diabetes mellitus, impaired glucose tolerance, hypertension, 
hypertriglyceridaemia, and hypercholesterolaemia were 
54.3, 9.3, 11.1, 9.8, 10.3 and 9.2%, respectively. The prevalence, however, of each of these conditions in its isolated 
form (free of the other five) was 29.0% for obesity, 1.3% for 
Type 2 diabetes, 1.8% for impaired glucose tolerance, 1.5% 
for hypertension, 1.0% for hypertriglyceridaemia, and 1.7% 
for hypercholesterolaemia. Two-by-two associations were 
even rarer. The large differences in prevalence between isolated and mixed forms indicate a major overlap among the six 
disorders in multiple combinations. In the isolated form, each 
condition was characterized by hyperinsulinaemia (both fasting and 2 h after oral glucose), suggesting the presence of insulin resistance. In addition, in any isolated condition most of 
the variables categorising other members of the sextet were 
still significantly altered in comparison with 1,049 normal 
subjects. In the whole of the subjects who presented with one 
or another disorder (1,881 of 2,930 or 64%), marked fasting 
and post-glucose hyperinsulinaemia was associated with 
higher body mass index, waist:hip ratio, fasting and post-glucose glycaemia, systolic and diastolic blood pressure, serum 
triglycerides and total cholesterol levels, and with lower 
HDL-cholesterol concentrations (all p < 0.001). We conclude that (1) insulin sensitivity, glucose tolerance, blood 
pressure, body fat mass and distribution, and serum lipids are 
a network of mutually interrelated functions; and (2) an insulin resistance syndrome underlies each and all of the six 
disorders carrying an increased risk of coronary artery disease. 
Key words: Hyperinsulinaemia, insulin resistance, syndrome 
X, San Antonio Heart Study. 
It has long been known that both hypertension and Type 2 
(non-insulin-dependent) diabetes mellitus are often associated with overweight [1, 2], and that hypertension is 
more prevalent among diabetic than non-diabetic individuals [3]. Hyperlipidaemia (high serum triglyceride or total 
cholesterol concentrations or both) is found with increased frequency in both diabetic [4] and hypertensive 
patients [5]. Thus, there seems to be a substantial overlap 
of disturbances of carbohydrate and lipid metabolism and 
of blood pressure in the general population, although, to 
our knowledge, a formal analysis of such clustering has 
not appeared in the literature. 
Recently, it has been suggested that hyperinsulinaemia 
may be the common element accounting for the association of obesity, Type 2 diabetes, and hypertension [6]. 
Obesity and Type 2 diabetes are classic states of insulin resistance [7], and recent evidence has shown that essential 
hypertension per se is often an insulin-resistant condition 
[8]. This has led Reaven [9] to hypothesise that insulin resistance aggregates with glucose intolerance, hypertension, and dyslipidaemia in a distinct syndrome (syndrome 
X). 
Diabetes, hypertension, and hypercholesterolaemia 
are unquestioned risk factors for cardiovascular disease 
(CVD) [10], whilst the evidence linking impaired glucose 
tolerance to CVD is less consistent [11]. The Framingham study has also established that high triglyceride 
levels, when coupled with low high-density-lipoprotein(HDL)-cholesterol concentrations, carry an increased risk of CVD [10]. Finally, recent data from a 
large population-based, follow-up study indicate that 
overweight, even of a minor degree, is an independent 
risk factor for ischaemic heart disease in women [12]. On 
the other hand, in two prospective epidemiologic studies 
[13, 14] plasma insulin concentration has emerged as an 
independent predictor of coronary heart disease. On 
these grounds, it is logical to suppose that the putative 
hyperinsulinaemia/insulin resistance syndrome may be 
associated with an increased risk of cardiovascular morbidity. 

E. Ferrannini et at.: The insulin resistance syndrome 
The present analysis of the San Antonio Heart Study 
database identifies and characterises an insulin resistance 
syndrome. 
Subjects and methods 
Subjects 
The San Antonio Heart Study is a population-based study of diabetes 
and cardiovascular diseases in Mexican-Americans and non-Hispanicwhites. From 1984 to 1988 households from several types of San 
Antonio census groups were randomly sampled: low-income census 
tracts (95% Mexican-American); middle-income tracts (50% Mexican-American and 50% non-Hispanic white); and suburban census 
tracts (10% Mexican-American, 90% non-Hispanic white) [15]. 
Stratified random sampling was used in the middle-income and suburban census tracts to ensure the inclusion of approximately equal 
numbers of each ethnic group in the study sample. All men and nonpregnant women 25 to 64 years of age were eligible for the study. 
Ethnicity was defined on the basis of a previously published algorithm which considered parental surnames and birthplaces, stated 
ethnicity of grandparents, and participant's preferred ethnic identity 
when it indicated a distinct national origin [16]. Persons who were 
identified as belonging to an ethnic group other than MexicanAmerican or non-Hispanic white are excluded from the present 
analysis. The study was approved by the Institutional Review Board 
of the University of Texas Health Science Center at San Antonio, 
and all subjects gave informed consent. 
Procedures 
Anthropometric measurements (height, weight, and waist/hip circumference ratio, WHR) were made with each participant wearing 
only underclothes and an examination gown [15]. Body mass index 
Table 1. Prevalence rates of obesity, Type 2 (non-insulin-dependent) diabetes, hypertension (HBP), impaired glucose tolerance 
(IGT), hypertriglyceridaemia (HTG), and hypercholesterolaemia 
(HCH) in 2,930 subjects ~ 
Prevalence Obesity Type 2 IGT HBP HTG HCH 
diabetes 
Overall 54.3 9.3 11.1 9.8 10.3 9.2 
Isolated 29.1 1.3 1.8 1.5 1.0 1.8 
2 x 2 associations: 
Type 2 diabetes 3.8 ..... 
(5.1) 
IGT 4.6 ..... 
(6.0) 
HBP 2.2 0.1 0.3 - - _ 
(5.3) (0.9) (1.1) 
HTG 3.0 0.2 0.2 0.1 - - 
(5.6) (1.0) (1.1) (1.0) 
HCH 2.4 0.2 0.1 03_ 0.5 - 
(5.0) (0.9) (1.0) (0.9) (1.0) 
% Multiple 
associations: 17 40 37 56 51 45 
Entries are actual, crude prevalence rates (in percent). The numbers in parentheses are the expected prevalence rates of 2 x 2 associations, calculated as the product of the overall prevalence rates of 
the two members of the pair. The last line shows the percentage of all 
the cases of each condition occurring in combinations of three or 
more with other conditions 
WHR Obesity Fast. G. , 
2-h G, ~Age 
2-h I. ~- J SBP 
Trigl. ~ HDL 
Chol. 
417 
Hypertension 
WHR Fast. G. BMI 
2-h I. "~~ j SBP 
Trigl. ~ HDL 
Chol. 
Fig. 1. Metabolic profile of obesity (top) and hypertension (bottom). 
The inner circle represents the mean value of each of the 12 variables 
(listed along the radii) in 1,049 healthy individuals; such mean values 
are set to be 100%. The symbols are percent differences in each variable between the patients groups and healthy controls (i.e. mean 
group value/mean control value times 100, plotted in log scale along 
the radii corresponding to the variable). Filled symbols and full lines 
identify the group of all subjects with obesity or hypertension; empty 
symbols and broken lines identify the subgroup of subjects with isolated obesity or hypertension (see the text for the definition of isolated). The variable in the box is the categorical (or coding) variable 
for the disease. BMI = body mass index; WHR = waist/hip ratio; 
Fast. G = fasting plasma glucose concentration; 2-hr G = plasma 
glucose concentration 2 h after an oral glucose load; Fast. I = fasting 
plasma insulin concentration; 2-hr I = plasma insulin concentration 
2 h after an oral glucose load; TG = serum triglyceride level; Chol = 
serum total cholesterol level; HDL = serum high-density-lipoprotein cholesterol level; DBP = diastolic blood pressure; SBP = systolic blood pressure 
(BMI) was calculated as weight (in kg) divided by height (in meters) 
squared. Obesity was defined as a BMI > 27 kg/m 2 ( > 26 kg/m 2 for 
women) [17]. Blood pressure was measured on the right arm of the 
seated participant following at least a 5-min rest using a random-zero 
sphygmomanometer (Hawksley-Gelman, London, UK). Three 
readings were recorded of the systolic (first phase) and diastolic 
(fifth phase) measured to the nearest even digit, and the subject's 
blood pressure was defined as the average of the second and third 
reading. Hypertension was defined according to the Hypertension 
Detection and Follow-up criteria (diastolic blood pressure 
> 95 mm Hg and/or currently taking antihypertensive medication) 
[181. 
Blood specimens were obtained following a 12-14 h fast for 
serum lipid, lipoprotein, and insulin and plasma glucose determinations. A 75-g glucose-equivalent load (Coladex or Orangedex, Cus- 

418 
tom Laboratories, Baltimore, Md., USA) was then administered, 
and blood specimens were obtained 2 h later for plasma glucose and 
insulin measurements. Methods for measurement of glucose, lipid, 
lipoprotein, and insulin have been published previously [15]. 
Diabetes was diagnosed according to the criteria of the World 
Health Organization (WHO) (fasting plasma glucose levels 
_> 7.8 mmol/1 or 2nd h plasma glucose _>ll.lmmol/1 [i9]. In 
previous reports, we have used National Diabetes Data Group 
(NDDG) criteria [2]. However, since the NDDG criteria do not have 
an unambiguous category for impaired glucose tolerance, we utilised 
the WHO criteria in the present report. The concordance between 
WHO and NDDG criteria for diagnosing diabetes in the San Antonio Heart Study is 98%. Subjects who did not meet these criteria but 
who were currently being treated with oral antidiabetic agents or 
insulin were also considered to have diabetes. Impaired glucose 
tolerance (IGT) was defined as a fasting plasma glucose 
<7.Smmol/1 and a 2nd h plasma glucose between 7.8 and 
11.1 mmol/1. Hypertriglyceridaemia was defined as a serum triglyceride concentration > 2.90 mmol/1, and hypercholesterolaemia as a 
serum total cholesterol concentration > 6.50 mmol/1. 
Statistical analysis 
Plasma insulin, glucose and triglyceride concentration values were 
log transformed to improve skewness. Group means were compared 
with the use of Student s t-test. Simultaneous adjustment for other 
variables was carried out by multiple linear regression. Data are 
given as mean + SEM. 
Type 2 diabetes 
WHR BMI 
FasLI" V,, k"~ \~~"'.~" J 1 DBP 
2-h L -~X~v,/ ~e~ SIP 
Trigl. ~ HDL Chol 
Impaired glucose tolerance 
WttR 
Fast. G. 
I 2-hG. Age 
Fast. I. DIP 
2-h I. ~BP 
w Chol. 
Fig.2. Metabolic profile of Type2 (non-insulin-dependent) 
diabetes (top) and impaired glucose tolerance (bottom). All symbols 
as in Figure i 
E. Ferrannini et al.: The insulin resistance syndrome 
Hypertriglyceridaemia 
WHR 
Fast. G. 
Fast'l" ; i ,~ / JDBP 
Chol. 
Hypercholesterolaemia 
WHR 
Fast. G. 
2-h G. 
BMI 
Age 
Fast. I. DBP 
2-h I. ~BP 
Fig. 3. Metabolic profile of hypertriglyceridaemia (top) and hypercholesterolaemia (bottom). All symbols as in Figure i 
Results 
The population sample consisted of 2,930 subjects (43% 
men, 68% Mexican-American), with a mean age of 
42.9 years. Over one-half of the population sample was 
obese; each of the other five conditions was present in 
roughly 10% ofallsubjects (Table 1). Only36% of all study 
subjects were 'normal' in that they were free of all six disorders. The crude prevalence rates of the six conditions in 
their'pure' or isolated form, i. e. associated with none of the 
other five, were much lower than the overall prevalence 
rates, by 50% in the case of obesity, 5-10 fold in the case of 
the others (Table 1). Two-by-two associations of isolated 
forms were even rarer, and in each case less frequent than 
expected by chance (Table 1). As a result, large proportions - ranging from 17% for obesity to 56% for hypertension- of the cases of each of the six conditions occurred in 
combination with three or more of the others. 
When the six groups of patients consisting of all cases 
with a condition were compared with the respective subgroups in which the disease was present in isolation 
(Figs. 1-3), the profile of the 12 measured (physiological 
and metabolic) variables was still qualitatively abnormal in 
the 'isolated' condition subgroups. The clinical characteristics of these latter are shown in Table 2 together with 
those of the normal subjects, while Table 3 lists the corre- 

E. Ferrannini et al.: The insulin resistance syndrome 
Insulin resistance syndrome 
WHR 
2-h G lge 
Fast. I. DBP 
2-h I. SBP 
Chol. 
Fig.4. Metabolic profile of all subjects with at ]east one of six conditions (obesity, hypertension, Type2 (non-insulin-dependent) 
diabetes, impaired glucose tolerance hypertriglyceridaemia, hypercholesterolaemia). All symbols as in Figure i 
sponding metabolic me asurements. Differences in age, sex 
or ethnicity ratio, and body mass index were present between each patient subgroup and the control subjects 
(Table 2). The waist/hip ratio was significantly higher than 
normal in obese (p < 0.005), diabetic (p < 0.01), glucoseintolerant (p < 0.02), and hypertensive (p = 0.02), but not 
in hypertriglyceridaemic or hypercholesterolaemic, patients. Because age, gender, ethnic origin, and body mass 
were all found to have a significant statistical influence on 
one or more of the metabolic variables (data not shown), 
comparisons between each patient subgroup and the control population were carried out after adjusting, by 
multiple linear regression, for age, sex, ethnicity, and BMI. 
The results are reported in Table 4 in terms of percent deviations from the mean reference values. They show that, 
even after the adjustments, each of the six isolated condi419 
tions was characterised by significant changes in several of 
the metabolic variables in addition to the defining variable 
for the condition itself. Thus, raised blood pressure was 
present also in 'pure' diabetic, IGT, or obese subjects, while 
increased fasting and 2nd h plasma glucose concentrations 
also occurred in 'pure' obese or hypertensive subjects. In 
particular, hyperinsulinaemia, fasting or post-glucose, was 
found in all patient groups (although in pure hypercholesterolaemia the adjusted difference from control subjects 
fell just short of full statistical significance,p = 0.11). 
When the 1,881 subjects with one or another disease 
combination (the 'insulin resistant' group) were compared with the 1,049 control subjects, all of the clinical and 
metabolic variables were significantly above normal (or 
below, in the case of serum HDL-cholesterol concentrations) (Fig. 4). Adjusting for age, sex, ethnicity, and BMI 
did not alter either the size or the level of statistical significance of the differences (Table 5). 
In the control group, numerous simple correlations 
were present among the measured variables, clinical and 
metabolic alike. In particular, when the fasting or postglucose plasma insulin concentration was set to be the dependent variable in a multiple regression model, 23 and 
53%, respectively, of the variance was explained by the 
other 13 measured variables (p < 0.001). In the 'insulin resistant' group, 50% of the variability of fasting insulin, and 
57% of that of post-glucose insulin, was statistically explained by the other measured variables (p < 0.001). 
Discussion 
The first result that stands out in the present analysis is the 
very high degree of overlap among the six conditions considered (obesity, Type 2 diabetes, hypertension, impaired 
glucose tolerance, hypertriglyceridaemia, and hyperTable 2. Characteristics of the groups studie@ 
n M/F MA/NHW Age BMI WHR 
(years) (kg/m 2) 
Normal 1.049 442/607 601/448 39.6 + 0.3 22.8 _+ 0.1 0.848 _+ 0.008 
Obese 852 354/498 630/222 41.3 + 0.4 31.1 + 0.1 0.898 + 0.010 
Diabetic 38 20/18 28/10 54.0 + 1.4 23.8 + 0.5 1.129 +_ 0.231 
Hypertensive 44 21/23 23/21 50.0 -+ 2.0 21.6 _+ 0.8 1.246 + 0.258 
Glucose intolerant 52 18/34 36/16 46.8 +_ 1.6 23.4 + 0.4 1.014 + 0.157 
Hypertriglyceridaemic 29 24/5 20/9 41.0 + 2.3 25.1 + 0.3 0.931 _+ 0.012 
Hypercholesterolaemic 52 17/35 24/28 48.3 _+ 1.6 23.5 -+ 0.4 0.997 + 0.157 
M/F = male/female ratio; MA/NHW = Mexican-American/non-Hispanic White ratio; BMI = Body mass index; WHR = waist/hip ratio 
Table 3. Metabolic parameters of the normal, obese, Type 2 diabetic, hypertensive, glucose-intolerant, hypertriglyceridaemic, and hypercholesterolaemic subgroups ~ 
FPG 2h-PG FPI 2h-PI TG Chol HDL SBP DBP 
(retool/l) (mmol/1) (pmol/l) (pmol/1) (mmol/1) (mmol/1) (mmol/1) (mmHg) (mmHg) 
Normal 4.56+0.02 5.02_+0.04 59"_ 1 368"+ 9 1.11"+0.02 4.78_+0.01 1.33+0.01 113-+0.4 69-+0.3 
Obese 4.76+0.02 5.41-+0.04 109_+ 4 635-+20 1.43+0.02 4.91-+0.03 1.17_+0.01 119_+0.5 73-+0.3 
Type 2 diabetic 8.26_+0.52 16.27_+0.90 88-+10 480-+91 1.55+0.10 5.24-+0.14 1.15+0.05 129+3 73+2 
Hypertensive 4.79 _+ 0.09 5.41 â€¢ 0.23 76 _+ 11 460 â€¢ 52 1.45 + 0.08 4.90 _+ 0.14 1.34 _+ 0.08 133 _+ 3 81 _+ 2 
Glucose intolerant 5.05 -+ 0.10 8.91 _+ 0.13 86 +_ 11 962 _+ 99 1.49 _+ 0.07 4.85 + 0.12 1.23 -+ 0.05 118 _+ 2 71 _+ 1 
Hypertriglyceridaemic 4.78 _+ 0.09 5.52 + 0.22 77 _+ 9 527 + 80 4.48 _+ 0.30 5.37 + 0.13 0.95 _+ 0.05 122_+ 2 72 _+ 2 
Hypercholesterolaemic 4.49 _+ 0.06 5.18 + 0.19 63 _ 6 433 + 46 1.60 _+ 0.07 7.06 + 0.08 1.40 + 0.06 120 _+ 2 72 _+ 1 
" FPG = fasting plasma glucose; 2h-PG - 2-h plasma glucose; FPI = fasting plasma insulin; 2h-PI = 2-h plasma insulin; TG = serum triglycerides; Chol = serum total cholesterol; HDL = serum HDL-cholesterol; SBP = systolic blood pressure; DBP = diastolic blood pressure 

420 
Table 4. Percent differences in metabolic parameters between the 
six patient subgroups and the control group ~ 
OB Type 2 HBP IGT HTG HCH 
Fasting glucose + 4 a + 66 a + 34 + 10 a + 3 - 2 
2-hglucose + 6" +198 a - 4 + 76 a + 12 ~ 0 
Fasting insulin + 80 a + 58 ~ + 35" + 43 ~ + 24 a + 20 
2-h insulin + 49 ~ - 5 + 36 a + 143 a + 41 ~ + 17 
Triglycerides +28 a + 13 a +18" + 26 a +274 a +37 a 
TotalChol. + 2 a 0 - 4 3 + 10 ~ +43 ~ 
HDL-Chol. -13 ~ - 15 ~ - 1 11 ~ - 21 ~ + 3 
SBP + 4 ~ + 8 ~ +13 a + 3 ~ + 4 a + 4 a 
DBP + 5 a + 2 +15 a + 2 + 1 + 4 ~ 
a Indicates that the percent change (from the control value) is significantly different from zero (p < 0.05 or less) after adjusting for 
age, sex, ethnicity, and BMI. Numbers in italics identify the classification variables. OB = obesity; Type 2 = Type 2 diabetes; HBP = 
hypertension; IGT = impaired glucose tolerance; HTG = hypertriglyceridaemia; HCH = hypercholesterolaemia; SBP = systolic 
blood pressure; DBP = diastolic blood pressure 
cholesterolaemia), a degree perhaps not fully appreciated 
until now. Each condition is defined by a conventional cutoff value of a continuous variable (e. g., body mass, glucose concentrations, blood pressure, etc.) rather than by 
the presence of a unique feature. Therefore, the observed 
superimposition pattern is dependent upon the chosen 
cut-off points. Shifting one or the other diagnostic criterion is likely to cause only quantitative, not qualitative differences in the overlap pattern. However, a very different 
prevalence of one condition would probably change the 
rate of occurrence of dual or multiple combinations. With 
regard to this, it is pertinent to note that the prevalence of 
Type 2 diabetes in the biethnic population of San Antonio 
is higher than in most westernised societies, on account of 
the enrichment of the Mexican-American group with 
diabetic individuals [15]. Since obesity, especially of the 
truncal variety, also is particularly frequent in MexicanAmericans [17], the results of the present analysis may not 
fully extend to other populations. 
Also striking is the observation that simple (two-bytwo) associations were all rarer than predicted by chance 
alone; this sort of spurious 'protection' against occurrence 
of two conditions together was actually the result of the 
high prevalence of triple or multiple combinations 
(Table 1). Thus, for all conditions but obesity, occurring as 
an isolated case in the cluster was an exceedingly infrequent event at the population level. One immediate practical corollary of these findings is that diagnosing any one 
of the six conditions in question should be sufficient indication to screen for the other five. Because of the extensive overlap, it was not surprising to find that each of the 
six conditions was characterized by multiple abnormalities (Figs. 1-3). More importantly, the analysis of the 
subgroups in which each condition was present alone revealed that, even in these isolated cases each categorical 
abnormality (e. g., blood pressure in hypertension) was accompanied by significant changes in several of the metabolic variables classifying other members of the sextet 
(after adjusting for age, gender and ethnic ratio, and 
BMI). Thus, lean, normotensive, normolipidaemic 
diabetic patients still had a significantly lower HDLcholesterol concentration and an increased systolic blood 
E. Ferrannini et al.: The insulin resistance syndrome 
pressure value; lean, non-diabetic, normolipidaemic 
hypertensive patients also had slight fasting hyperglycaemia and hyperlipidaemia when compared with the 
control subjects (Table 4). These results, and the fact that 
the 12 measured variables showed a high degree of interrelatedness even in the group of healthy control subjects, 
suggest that the network of connections among the six 
conditions may simply be an amplification of normal links 
among the underlying physiological functions [5]. The 
physiological basis of several such relationships is well established. For example, a rise in piasma glucose levels can 
directly result from tissue refractoriness to insulin action 
on glucose uptake; elevated glycaemia then elicits a 
heightened insulin secretory response, which in turn is a 
stimulus for hepatic VLDL-triglyceride production [20- 
22]. Also, hyperinsulinaemia may raise blood pressure by 
a variety of mechanisms including renal sodium conservation and adrenergic activation [23]. If, then, the physiologic system explored by these parameters is indeed a network, pulling one element out of the normal boundaries 
will act upon the connecting arms to drag other neighbouring elements into the 'abnormal' domain. For 
example, if a strong genetic pressure drives plasma glucose into the diabetic range, blood pressure and lipids will 
trail behind, occasionally crossing the diagnostic 
Table S. Clinical and metabolic characteristics of the insulin resistant group and their percent differences from the control group" 
Mean â€¢ SEM Percent differ- p value 
ence from controls 
Number 1881 - 
M/F 815/1061 - 
MA/NHW 1395/481 - 
Age (years) 45.3 _+ 0.3 - 
BMI (kg/m 2) 30.5 + 0.1 
WHR 0.932 + 0.012 + 15% < 0.0001 
Fasting glucose 
(mmol/1) 5.53_+ 0.05 + 5% < 0.0001 
2-h Glucose 
(mmol/1) 7.80 + 0.11 + 20% < 0.0001 
Fasting insulin 
(pmol/l) 129 â€¢ 3 + 36% < 0.0001 
2-h Insulin 
(pmol/l) 787 â€¢ 18 + 37% < 0.0001 
Triglycerides 
(mmol/l) 2.01 â€¢ 0.03 + 50% < 0.0001 
Total cholesterol 
(mmol/l) 5.33 â€¢ 0.03 + 10% < 0.0001 
HDL-cholesterol 
(mmol/1) 1.14 â€¢ 0.01 - 8% < 0.0001 
SBP (mmHg) 123+0.4 + 4% <0.0001 
DBP (mmHg) 74â€¢ + 4% <0.0001 
The comparison with the control group is made after adjusting for 
age, sex, ethnicity, and BMI, and calculated at the mean population 
age (43 years) and BMI (27.9 kg/m 2) for a male Mexican-Americansubject. M/F = male/female ratio; MA/NHW = Mexican-American/non-Hispanic white; BMI = body mass index; WHR = 
waist/hip ratio; SBP = systolic blood pressure; DBP = diastolic 
blood pressure 

E. Ferrannini et al.: The insulin resistance syndrome 
threshold of clinical hypertension and dyslipidaemia. 
Thus, on a priori grounds it is highly unlikely that any of 
this kindred of disorders will occur in true isolation, i.e. 
with no changes (or opposite changes) in the tied metabolic/haemodynamic functions. 
The other major finding of this study is that, while insulinaemia itself is not a classification variable for any disease, hyperinsulinaemia, fasting or post-glucose, was present in all the subgroups of isolated conditions. It was the 
common denominator of the sextet. Under most circumstances, a raised plasma insulin concentration implies the 
presence of insulin resistance, and, in fact, represents an 
adaptive response to the reduced sensitivity to the hormone [24]. Previous studies using the euglycaemic insulin 
clamp technique [25] have shown that insulin resistance is 
present in non-diabetic, normotensive obese subjects [26], 
in lean, normotensive patients with Type 2 diabetes [27] or 
impaired glucose tolerance [28, 29], in lean, normotensive 
hypertriglyceridaemic subjects [30], and in lean, nondiabetic, normolipidaemic hypertensive patients [8, 31]. 
In these highly selected patient groups, the insulin resistance has been thought of as primary [9]. Direct evidence 
that pure, isolated hypercholesterolaemia may be associated with insulin resistance is lacking, but the data in 
Table 4 suggest that this might be the case. Thus, at least 
five of the six conditions considered here have already entered the list of primary insulin resistant states in humans. 
Therefore, the present data on hyperinsulinaemia very 
likely illustrate the relationship of insulin resistance with 
the physiological and metabolic changes found in the 
member conditions of the sextet. It is legitimate to collectively indicate the sextet as a primary insulin resistance 
syndrome (Fig. 4), in which different features (e. g., hyperglycaemia or high blood pressure) dominate the clinical 
picture in different patients. This concept is an extension 
of the insulin resistance syndrome hypothesised by 
Reaven [9], and alluded to by Lind et al. [32], and certainly 
is not exhaustive: other disorders with genetic imprint, insulin resistance and atherogenic potential may be included. 
The question then arises: is insulin resistance one common result of the six conditions (e. g., via hyperglycaemia 
in Type 2 diabetes, or high blood pressure in hypertension), or is it a basic cellular defect, parent to the conditions? Available evidence appears to be insufficient to 
answer this question. Some information would favour a 
primacy of insulin resistance. Thus, at least in nondiabetic Pima Indians, in vivo insulin action is a familial 
characteristic [33]. Furthermore, non-diabetic relatives of 
Type 2 diabetic patients present hyperinsulinaemia [34] 
and insulin resistance [35], and hyperinsulinaemia predicts the subsequent development of Type 2 diabetes [36]. 
Parental history of Type 2 diabetes is associated with 
higher prevalence of hypertension and lipid abnormalities 
in non-diabetic probands [37]. Hyperinsulinaemic, but 
otherwise healthy, individuals have higher plasma glucose 
and lipid levels and blood pressure values [38]. In at least 
one variant of familial dyslipidaemic hypertension, hyperinsulinaemia is found that is not fully explained by obesity 
[39]. On the other hand, insulin resistance can be entirely 
acquired - as presumably are many cases of obesity in421 
duced by excess caloric intake - and yet display the full 
range of associated abnormalities of glucose and lipid metabolism and blood pressure. The present analysis of 
cross-sectional data cannot offer any clue as to the nature 
of the observed associations among diseases or the relation of each of them to insulin resistance. Genetic heterogeneity, environmental factors, and gene-environment 
interactions are known to determine the natural history of 
obesity, Type2 diabetes, hypertension, and dyslipidaemias [40-44]. Their multiple associations may likewise reflect true genetic linkage, cause-effect relationships, or both. At present, it seems both accurate and 
prudent to state that the presence of insulin resistance in 
the sextet can have a variable value - of a predisposing or 
aggravating factor- in the different member diseases and, 
possibly, within the affected individuals of each disease. 
Whatever the case, the general pattern of abnormalities in the insulin resistant group (Fig. 4) is a highly 
atherogenic risk profile, in support of the contention that 
this syndrome is a precursor of CVD. Longitudinal studies 
are needed to address what appears to be the crucial issue: 
is an insulin resistant individual 'bound' to develop a 
string of abnormalities ultimately leading to CVD ? 
Acknowledgement. This work was supported by grant HL 24799. 
References 
1. Sims EAH, Berchtold P (1982) Obesity and hypertension. Mechanisms and implications for management. JAMA 247:49-52 
2. National Diabetes Data Group (1979) Classification of diabetes 
mellitus and other categories of glucose intolerance. Diabetes 28: 
1039 1055 
3. Fuller JH (1985) Epidemiology of hypertension associated with 
diabetes mellitus. Hypertension 7 [Suppl. II]: II3~ 
4. Nikkila EA (1984) Plasma lipid and lipoprotein abnormalities in 
diabetes. In: Jarrett RJ (ed) Diabetes and heart disease. Elsevier, 
Amsterdam, pp 133-167 
5. Stamler J, Berkson D, Dyer A, Lindberg HA (1975) Relationship of multiple variables to blood pressure findings from four 
Chicago epidemiologic studies. In: Paul O (ed) Epidemiology 
and control of hypertension. Stratton, New York, pp 307-356 
6. Modan M, Halkin H, Almog S, Lusky A, Eskol A, Shefi M, Shitrit A, Fuchs L (1985) Hyperinsulinaemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 75:809-817 
7. DeFronzo RA, Ferrannini E (1982) The pathogenesis of non-insulin dependent diabetes. An update. Medicine 61:125-135 
8. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini 
M, Graziadei L, Pedrinelli R, Brandi LS, Bevilacqua S (1987) Insulin resistance in essential hypertension. N Engl J Med 317: 350- 
357 
9. Reaven GM (1988) Role of insulin resistance in human disease. 
Diabetes 37:1595-1607 
10. Castelli WP (1984) Epidemiology of coronary heart disease: the 
Framingham study. Am J Med 76 [Suppl. 2A]: 4-12 
11. Stamler R, Stamler J (1979) Asymptomatic hyperglycemia and 
coronary heart disease. J Chron Dis 32:829-837 
12. Manson JE, Colditz GA, Stampfer M J, Willett WC, Rosner B, 
Monson RR, Speizer FE, Hennekens CH (1990) A prospective 
study of obesity and risk of coronary heart disease in women. N 
Engl J Med 322:882-889 
13. PySr~il~i K (1979) Relationship of glucose tolerance and plasma 
insulin to the incidence of coronary heart disease: results from 
two population studies in Finland. Diabetes Care 2:121-141 

422 
14. Ducimetiere R Eschwege E, Papoz L, Richard JL, Claude JR, 
Rosselin G (1980) Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease 
mortality in a middle-aged population. Diabetologia 19:205-210 
15. Haffner SM, Stern MR Hazuda HR Pugh JA, Patterson JK 
(1986) Hyperinsulinaemia in a population at high risk for non-insulin-dependent diabetes mellitus. N Engl J Med 315:220-224 
16. Hazuda HR Comeaux P J, Stern MR Haffner SM, Eifler CW, 
Rosenthal M (1986) A comparison of three indicators for identifying Mexican Americans in epidemiologic research: methodological findings from the San Antonio Heart Study. Am J Epidemio1123:96-112 
17. Stern MR Patterson JK, Mitchell BD, Haffner SM, Hazuda HP 
(1990) Overweight and mortality in Mexican Americans. Int J 
Obes 14:623 629 
18. Hypertension Detection and Follow-up Program Cooperative 
Group (1977) Blood pressure studies in 14 communities: a twostage screen for hypertension. JAMA 237:2385-2391 
19. World Health Organization Expert Committee (1980) Second 
Report on Diabetes Metlitus. Geneva, WHO, Tech. Rep. Ser. 
No. 646 
20. Tobey TA, Greenfield M, Kraemer F, Reaven GM (1981) Relationship between insulin resistance, insulin secretion, very low 
density lipoprotein kinetics and plasma triglyceride levels in normotriglyceridemic man. Metabolism 30:165-171 
21. Reaven GM, Lerner RL, Stern MR Farquhar JW (1967) Role of 
insulin in endogenous hypertriglyceridemia. J Clin Invest 46: 
1756-1767 
22. Steiner G, Vranic M (1982) Hyperinsulinemia and hypertriglyceridemia, a vicious circle with atherogenic potential. Int J Obes 6 
[Suppl. 1]: 117-124 
23. Ferrannini E, DeFronzo RA (1989) The association of hypertension, diabetes, and obesity: a review. J Nephrol 1:3-15 
24. DeFronzo RA (1988) The triumvirate: 13-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37:6674587 
25. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. 
Am J Physio1237:E214-E223 
26. Kolterman OG, Insel J, Saekow M, Olefsky JM (1980) Mechanisms of insuhn resistance in human obesity. Evidence for receptor and postreceptor defects. J Clin Invest 65:1272-1284 
27. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, 
Ferrannini E, DeFronzo RA (1989) Glucose and free fatty acid 
metabolism in non-insulin dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84: 
205-213 
28. Bogardus C, Lillioja S, Howard B, Reaven GM, Mott D (1984) 
Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in non-diabetic and non-insulin-dependent diabetic subjects. J Clin Invest 74:1238-1246 
29. Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, 
Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C 
(1988) Impaired glucose tolerance as a disorder of insulin action: 
longitudinal and cross-sectional studies in Pima Indians. N Engl 
J Med 318:1217-1225 
30. Steiner G, Morita S, Vranic M (1980) Resistance to insulin but 
not glucagon in lean human hypertriglyceridemics. Diabetes 29: 
899-905 
E. Ferrannini et al.: The insulin resistance syndrome 
31. Shen DC, Shieh S-M, Fuh MT, Chert Y-DI, Reaven GM (1988) 
Resistance to insulin-stimulated glucose uptake in patients with 
hypertension. J Clin Endocrinol Metab 66:580-583 
32. Lind L, Jakobsson S, Lithell H, Wengle B, Ljunghall S (1988) Relation of serum calcium to metabolic risk factors for cardiovascular disease. Br Med J 297:960.963 
33. Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WGH, 
Knowler WC, Bennett PH, Moll R Bogardus C (1987) In vivo insulin action is familial characteristic in nondiabetic Pima Indians. 
Diabetes 36:1329-1335 
34. Haffner SM, Stern MR Hazuda HR Mitchell BD, Patterson JK 
(1988) Increased insulin concentrations in nondiabetic offspring 
of diabetic parents. N Engl J Med 319:1297-1301 
35. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, 
Widen E, Schalin C, Groop L (1989) Early metabolic defects in 
persons at increased risk for non-insulin-dependent diabetes 
mellitus. N Engl J Med 321:33%343 
36. Haffner SM, Stern MR Mitchell BD, Hazuda HR Patterson JK 
(1990) Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat 
distribution. Diabetes 39:283-288 
37. Haffner SM, Stern MR Hazuda HP, Mitchell BD, Patterson JK, 
Ferrannini E (1989) Parental history of diabetes is associated 
with increased cardiovascular risk factors. Arteriosclerosis 9: 
928-933 
Zavaroni I, Bonora E, Pagliara Met al. (1989) Risk factors for 
coronary artery disease in healthy people with hyperinsulinaemia and normal glucose tolerance. N Engl J Med 320: 202- 
206 
Hurt SC, Wu LL, Hopkins PN et al. (1989) Apolipoprotein, low 
density lipoprotein subfraction, and insulin associations with 
familial combined hyperlipidemia. Study of Utah patients with 
familial dyslipidemic hypertension. Arteriosclerosis 9:335-344 
Stunkard AJ, Sorensen TIA, Hanis C, Teasdale TW, Chakraborty R, Schull W J, Schulsinger F (1986) An adoption study of 
human obesity. N Engl J Med 314:193-198 
Foster DW (1989) Diabetes mellitus. In: Scriver CR, Beaudet 
AL, Sly WS, Valle D (eds) The metabolic basis of inherited diseases, 6th edn. McGraw-Hill, New York, p 384 
Johnson BC, Epstein FH, Kjelsberg M (1965) Distribution and 
familial studies of blood pressure and serum cholesterol levels in 
a total community, Tecumseh, Michigan. J Chronic Dis 18: 14% 
160 
Iselius L, Morton NE, Rao DC (1983) Family resemblance for 
blood pressure. Hum Hered 33:277-286 
Grundy SM (1987) Disorders of lipids and lipoproteins. In: Stein 
JH (ed) Internal medicine, 2nd edn. Little, Brown and Company, 
Boston, pp 2035-2052 
38. 
39. 
40. 
41. 
42. 
43. 
44. 
Received: 22 October 1990 
and in revised form: 17 January 1991 
Dr. E. Ferrannini 
C.N.R. Institute of Clinical Physiology 
Via Savi, 8 
1-56100 Pisa 
Italy 

